Trial Profile
A phase I clinical trial of NX210 in spinal cord injury
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs NX 210 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions
- 16 Nov 2017 New trial record